Imbalanced effector and regulatory cytokine responses may underlie mycobacterial immune restoration disease
© Lim et al; licensee BioMed Central Ltd. 2008
Received: 09 January 2008
Accepted: 29 April 2008
Published: 29 April 2008
Immune restoration disease (IRD) is an adverse consequence of antiretroviral therapy, where the restored pathogen-specific response causes immunopathology. Mycobacteria are the pathogens that most frequently provoke IRD and mycobacterial IRD is a common cause of morbidity in HIV-infected patients co-infected with mycobacteria. We hypothesised that the excessive effector immune response in mycobacterial IRD reflects impaired regulation by IL-10.
We studied two patients who experienced mycobacterial IRD during ART. One patient developed a second episode of IRD with distinct clinical characteristics. Findings were compared with patients 'at risk' of developing IRD who had uneventful immune recovery. Peripheral blood mononuclear cells (PBMC) from all subjects were stimulated with mycobacterial antigens in the form of purified protein derivative (PPD). Supernatants were assayed for IFNγ and IL-10. In response to PPD, PBMC from IRD patients generated IFNγ during the first IRD episode, whilst cells from non-IRD controls produced more IL-10.
We present preliminary data from two HIV-infected patients showing an imbalance between IFNγ and IL-10 responses to mycobacterial antigens during mycobacterial IRD. Our findings suggest that imbalanced effector and regulatory cytokine responses should be investigated as a cause of IRD.
Immune restoration disease (IRD) after commencing antiretroviral therapy (ART) is considered to be a consequence of restoring an immune response against an active (often quiescent) infection by an opportunistic pathogen, or antigens of non-viable pathogens, that results in immunopathology [1, 2]. Mycobacterium tuberculosis (Mtb) and non-tuberculous mycobacteria are pathogens that commonly provoke IRD [3, 4]. Patients experiencing mycobacterial IRD often present with fever and lymphadenitis, but may also have pulmonary infiltrates or inflammatory masses. A cutaneous delayed-type hypersensitivity (DTH) response to mycobacterial antigens is a characteristic finding [1, 5, 6], and coincides with excessive production of Type 1 (Th1) cytokines , probably by memory CD4+ T cells. However, the immunopathogenesis of mycobacterial IRD is not fully understood and may be variable since the clinical presentations can be diverse. Tissue inflammation presenting during the first few months of ART usually has the features of a DTH immune response , but some patients present with suppurating lymphadenitis and/or disease that presents later [8–10].
Immunity to mycobacterial infections is influenced by the counteracting effects of effector cytokines and regulatory cytokines, such as interleukin (IL)-10, in patients with and without HIV infection [11–14]. As IL-10 provides a regulatory mechanism for Th1 memory CD4+ T cell responses [15, 16], we hypothesised that the excessive effector response in mycobacterial IRD reflects impaired regulation by IL-10. We present preliminary data from two HIV-infected patients showing an imbalance between interferon-gamma (IFNγ) and IL-10 responses to mycobacterial antigens during mycobacterial IRD.
Patient 1 (P1) was a 48-year-old Caucasian male who developed Mycobacterium celatum IRD one month after commencing ART. This case has been described previously . Briefly, he presented with a CD4+ T cell count of 48/μL and plasma HIV RNA level >100,000 copies/mL. He developed fever on day 11 of ART and sputum collected on each of the following 3 days yielded M. celatum. Chest radiography and a computer tomography (CT) scan revealed areas of consolidation in both lungs. On day 27 of ART his CD4+ T cell count had increased to 189/μL, his plasma HIV RNA level had decreased to 933 cells/μL and DTH skin testing demonstrated an 18 mm response to purified protein derivative (PPD) and a 10 mm response to Mycobacterium avium antigen. Prednisone was administered and the patient's symptoms resolved completely.
Patient 2 (P2) was a 51-year-old Caucasian male who presented with a CD4+ T cell count of 16/μL and plasma HIV RNA level of 54,954 copies/mL. Two routine blood cultures taken at initial presentation grew Mycobacterium avium complex (MAC). He was treated with ethambutol, rifabutin and azithromycin. DTH skin tests with M. avium antigen and PPD both gave reactions of 0 mm, demonstrating anergy towards mycobacterial antigens.
Six weeks after initial presentation, he commenced ART consisting of efavirenz, zidovudine and lamivudine. Four months later, he was seen for a routine assessment and had no specific complaints. However, a right axillary lymph node was detected and the liver was palpable. Blood tests revealed a haemoglobin level of 99 g/L, serum CRP level of 51 mg/L and ESR of 100 mm/hr but normal LDH and liver function tests. His CD4+ T cell count was 42/μL and plasma HIV RNA level <50 copies/mL. An aspirate of the right axillary lymph node and a sputum sample both grew MAC. Blood cultures were negative. A chest CT scan revealed marked axillary and mediastinal lymphadenopathy. On this occasion, DTH skin testing gave reactions of 18 mm to M. avium antigen and 17 mm to PPD. He continued on anti-MAC antibiotics and commenced prednisolone therapy for likely MAC IRD. After 4 weeks the lymphadenopathy was resolving and CRP was normal. Plasma HIV RNA remained undetectable.
He had an uneventful course for 6 months until he represented unwell with 10 kg weight loss and night sweats. There was a 5 × 6 cm draining lymph node in the cervical region and a chronic discharging sinus in the right axilla. No other lymphadenopathy or organomegaly was palpable. Plasma HIV RNA was still undetectable; however the CD4+ T cell count was only 42/μL. A surgically resected lymph node revealed the presence of mycobacteria, but these could not be cultured. A granulomatous inflammatory response with necrosis, neutrophils and karryorhectic debris (dead neutrophils) at the centre of necrotic areas was also demonstrated. Tests for Mtb DNA in the lymph node, blood cultures for mycobacterial infection and a whole blood IFN-γ release assay with Mtb-specific antigens (QuantiFERON-TB Gold, Cellestis) were all negative. The serum CRP level was normal. DTH skin testing revealed an absent response to M. avium antigen and only a 7 mm reaction to PPD. He continued anti-MAC antibiotics and recommenced prednisolone therapy.
P1 experienced disseminated CMV disease prior to ART. To demonstrate that high levels of PPD-induced IFNγ production during his IRD was specific for the provoking pathogen, his PBMC were stimulated with CMV antigen. At the time of IRD, IFNγ was undetectable (<15 pg/mL) in the supernatants of CMV-stimulated cultures.
The second episode of IRD in P2 had different immunological characteristics to the first episode. IFNγ was not detected in supernatants of PBMC stimulated with PPD (Figure 1). However, IL-10 was detectable after 24, 48 or 72 hours stimulation (Figure 2). These IL-10 responses remained steady after 12 months on ART.
We present clinical and laboratory data from two patients with mycobacterial IRD, and appropriate controls, that support our hypothesis that IRD might reflect failure to produce sufficient IL-10 during restoration of mycobacteria-specific effector CD4+ T cell responses after commencing ART. We used PPD as an antigen to investigate pathogen-specific cytokine responses because we and others have shown that IRD associated with infection by Mtb and non-tuberculous mycobacteria (NTM) is associated with increased cellular immune responses to PPD [1, 2, 5, 7, 17]. Our controls were considered to be 'at risk' of developing IRD because we have previously shown that 'subclinical' infection with NTM is almost inevitable when HIV patients in our population are severely immunodeficient .
PPD-stimulated PBMC from both IRD patients produced less IL-10 than IFNγ during the first episode of IRD. High IFNγ production has been previously demonstrated in Mtb IRD . In contrast, IL-10 production by PPD-stimulated PBMC predominated in donors without IRD, suggesting sufficient regulatory control. The more vigorous IFNγ response in P1 relative to P2 may reflect better immune reconstitution as P1 experienced an approximately 4-fold increase in CD4+ T cell count after only 1 month of ART, while P2 had a persistently low CD4+ T cell count even after 10 months of ART. However, both patients displayed strong DTH skin test responses at the time of IRD, indicating that restoration of cellular immune function may not correlate with circulating CD4+ T cell counts. Higher production of IFNγ relative to IL-10 in P3 may reflect Mtb-specific immunological memory as a consequence of previous tuberculosis.
We were able to study two episodes of IRD in P2. His second IRD episode had different immunological and clinical characteristics to the first episode. A cutaneous DTH response to M. avium antigen was absent. High IL-10 and low IFNγ production were demonstrated following PPD stimulation of PBMC. With the clinical findings of sinus formation from lymph nodes and predominance of neutrophils in the lymph node biopsy, our data suggests that this episode did not fit the "classical" Th1 presentation of mycobacterial IRD. Investigation of other effector T cells might be informative, particularly Th17 cells as these cells may promote neutrophil responses .
In conclusion, we suggest that future studies of the immunopathogenesis of mycobacterial IRD should include analyses of mycobacteria-specific effector and regulatory cytokine responses.
Laboratory methods and controls
PBMC were cryopreserved prior to ART (P1 only), at each IRD episode and after 12 months on ART. Six male HIV-infected patients who did not develop IRD after commencing ART (non-IRD patients, P3 to P8) were sampled prior to ART and approximately 6 months later. All non-IRD patients had CD4+ T cell counts below 100/μL and plasma HIV RNA levels >4 log10 copies/mL before ART. At the second PBMC collection, 5 non-IRD patients had achieved and maintained plasma HIV RNA levels of <50 copies/mL, while the remaining patient had achieved and maintained plasma HIV RNA levels >2 logs below his baseline level. Four non-IRD patients experienced at least a four-fold increase in their CD4+ T cell count after 6 months of ART (total CD4+ T cell count increased to above 150/μL), while the other 2 patients increased their CD4+ T cell counts less than three-fold (total CD4+ T cell count remained below 100/μL). Non-IRD patient 3 (P3) had a history of treated tuberculosis several years earlier.
PBMC were isolated by Ficoll separation of heparinised whole blood and cryopreserved in RPMI with 10% dimethylsulfoxide. Thawed PBMC were cultured in 10% FCS/RPMI at 2.5 × 106 cells/mL with 10 μg/mL PPD (Statens Serum Institute) or CMV antigen (AD169 lysate), and 12.5 μg/mL phytohaemaggutinin (mitogen control) at 37°C for 24 hours. Supernatants were assayed by ELISA for IFNγ (BD Biosciences) and IL-10 (R&D Systems). Unstimulated cells were cultured in parallel.
In a second experiment, PBMC from P2, P3, a HIV-negative patient with active tuberculosis and two uninfected donors were cultured at 1 × 106 cells/mL with PPD over a 72-hour time-course. Both uninfected donors were known to have PPD-specific cells detectable by ELISpot. Supernatants were assayed for IL-10 at 24-hour intervals by cytometric bead array (BD Biosciences).
Informed consent was obtained from all individuals and the study was approved by the Ethics Committee of Royal Perth Hospital.
We thank the staff of Immunology (Sir Charles Gairdner Hospital) for the collection of blood samples and Steven Roberts for performing Ficoll separations. This is publication 2007-53 (Clinical Immunology and Immunogenetics, Royal Perth Hospital). This study was supported by a grant from the National Health and Medical Research Council of Australia (404028 to MAF and PP).
- French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, Price P, Flexman JP, Tay-Kearney ML: Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000, 1 (2): 107-115. 10.1046/j.1468-1293.2000.00012.xView ArticlePubMed
- French MA, Price P, Stone SF: Immune restoration disease after antiretroviral therapy. AIDS. 2004, 18 (12): 1615-1627. 10.1097/01.aids.0000131375.21070.06View ArticlePubMed
- Lawn SD, Bekker LG, Miller RF: Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005, 5 (6): 361-373. 10.1016/S1473-3099(05)70140-7View ArticlePubMed
- Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC, Visnegarwala F, Trautner BW: Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002, 81 (3): 213-227. 10.1097/00005792-200205000-00005View Article
- French MA, Mallal SA, Dawkins RL: Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS. 1992, 6 (11): 1293-1297. 10.1097/00002030-199211000-00009View ArticlePubMed
- Narita M, Ashkin D, Hollender ES, Pitchenik AE: Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998, 158 (1): 157-161.View ArticlePubMed
- Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, Gicquel B, Vicaut E, Lagrange PH, Sereni D, Autran B: Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS. 2006, 20 (2): F1-7. 10.1097/01.aids.0000202648.18526.bfView ArticlePubMed
- Guex AC, Bucher HC, Demartines N, Fluckiger U, Battegay M: Inflammatory bowel perforation during immune restoration after one year of antiretroviral and antituberculous therapy in an HIV-1-infected patient: report of a case. Dis Colon Rectum. 2002, 45 (7): 977-978. 10.1007/s10350-004-6339-1View ArticlePubMed
- Huyst V, Lynen L, Bottieau E, Zolfo M, Kestens L, Colebunders R: Immune reconstitution inflammatory syndrome in an HIV/TB co-infected patient four years after starting antiretroviral therapy. Acta Clin Belg. 2007, 62 (2): 126-129.View ArticlePubMed
- Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, Hamill RJ: Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. Aids. 2005, 19 (4): 399-406. 10.1097/01.aids.0000161769.06158.8aView ArticlePubMed
- Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, Dascher CC, Berezovskaya A, Rousset D, Reynes JM, Goldfeld AE: IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest. 2000, 105 (9): 1317-1325. 10.1172/JCI9918PubMed CentralView ArticlePubMed
- Demissie A, Abebe M, Aseffa A, Rook G, Fletcher H, Zumla A, Weldingh K, Brock I, Andersen P, Doherty TM: Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol. 2004, 172 (11): 6938-6943.View ArticlePubMed
- Muller F, Aukrust P, Lien E, Haug CJ, Froland SS: Enhanced interleukin-10 production in response to Mycobacterium avium products in mononuclear cells from patients with human immunodeficiency virus infection. J Infect Dis. 1998, 177 (3): 586-594.View ArticlePubMed
- Sahiratmadja E, Alisjahbana B, de Boer T, Adnan I, Maya A, Danusantoso H, Nelwan RH, Marzuki S, van der Meer JW, van Crevel R, van de Vosse E, Ottenhoff TH: Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect Immun. 2007, 75 (2): 820-829. 10.1128/IAI.00602-06PubMed CentralView ArticlePubMed
- Kvale EO, Floisand Y, Lund-Johansen F, Rollag H, Farkas L, Ghanekar S, Brandtzaeg P, Jahnsen FL, Olweus J: Plasmacytoid DCs regulate recall responses by rapid induction of IL-10 in memory T cells. Blood. 2007, 109 (8): 3369-3376. 10.1182/blood-2006-06-031484View ArticlePubMed
- O'Garra A, Vieira P: T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 2007, 7 (6): 425-428. 10.1038/nri2097View ArticlePubMed
- Bell HC, Heath CH, French MA: Pulmonary Mycobacterium celatum immune restoration disease: immunopathology and response to corticosteroid therapy. AIDS. 2005, 19 (17): 2047-2049. 10.1097/01.aids.0000191228.36797.5bView ArticlePubMed
- Mallal SA, James IR, French MA: Detection of subclinical Mycobacterium avium intracellulare complex infection in immunodeficient HIV-infected patients treated with zidovudine. Aids. 1994, 8 (9): 1263-1269.View ArticlePubMed
- Witowski J, Ksiazek K, Jorres A: Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci. 2004, 61 (5): 567-579. 10.1007/s00018-003-3228-zView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.